BIOMAT Database Logo BIOMAT Database Logo

[Effect of azosemide and furosemide on body fluid distribution and vasoactive hormones]. 1991

Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Second Department of Internal Medicine, Kagawa Medical School, Osaka University.

We examined the diuretic action of orally administered azosemide (AZ: 60 mg) and furosemide (FM: 40 mg) and their effects on body fluid distribution and circulatory vasoactive hormones in normal male volunteers. Urine volume and urinary sodium excretion were increased, peaking during 0 to 2 hours in FM and 2 to 4 hours in AZ in response to administration of both diuretics. The cumulative urine volume and urinary sodium excretion for 8 hours showed no significant difference between AZ and FM. Total body water (TBW) was measured by the dynamic distribution of deuterium oxide and a percentage change in circulating plasma volume (ICG ratio) was determined by using indocyanine green. The decrease in TBW and ICG ratio was detected in proportion to the increase in urine volume after administration of AZ and FM. Plasma renin activity (PRA) and plasma concentration of aldosterone (PAC), angiotensin II (ANG II) and arginine vasopressin (AVP) were elevated in response to the reduction in ICG ratio by both diuretics. The responses of PRA, PAC and ANG II to AZ were delayed about 2 hours as compared with those of FM. The increase in AVP with FM was significantly greater than that with AZ detected 2 hours after administration. The elevation of AVP in AZ was delayed and blunted compared with FM. These data indicate that the difference in diuretic property of AZ and FM may induce different stimulation to the secretion of vasoactive hormones through the changes in body fluid distribution and these hormones might modify the anti-edematic effect of AZ and FM.

UI MeSH Term Description Entries
D008297 Male Males
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D001826 Body Fluids Liquid components of living organisms. Body Fluid,Fluid, Body,Fluids, Body
D005665 Furosemide A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY. Frusemide,Fursemide,Errolon,Frusemid,Furanthril,Furantral,Furosemide Monohydrochloride,Furosemide Monosodium Salt,Fusid,Lasix
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D001127 Arginine Vasopressin The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE. Argipressin,Vasopressin, Arginine,Arg-Vasopressin,Argipressin Tannate,Arg Vasopressin

Related Publications

Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Azosemide, a "loop" diuretic, and furosemide.
April 1979, Clinical pharmacology and therapeutics,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
[The effect of azosemide and furosemide on the renal excretion of amino acids].
April 1983, Casopis lekaru ceskych,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
[Effect of iodine on body fluid distribution].
June 1958, Wiener klinische Wochenschrift,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Effect of a hepatoprotective agent, YH-439, on the pharmacokinetics of furosemide and azosemide in rats.
February 1996, Research communications in molecular pathology and pharmacology,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Effect of changes in body posture on vasoactive hormones in pre-eclamptic women.
November 2004, Journal of human hypertension,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
[Effect of neurohypophyseal hormones on body water distribution in rats].
August 1976, Fiziologicheskii zhurnal SSSR imeni I. M. Sechenova,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Effect of furosemide on cerebrospinal fluid composition.
June 1984, Respiration physiology,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Vasoactive effects of furosemide.
April 1980, Angiology,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
Influence of acute diuresis on calcium balance--a comparative study of furosemide and azosemide.
August 1984, International journal of clinical pharmacology, therapy, and toxicology,
Y Takamitsu, and S Yuasa, and S Miki, and T Yura, and N Takahashi, and K Uchida, and H Tanaka, and T Yamamoto, and H Kiyomoto, and H Matsuo
[Effect of Hespander on body fluid distribution in normal dogs].
April 1972, Masui. The Japanese journal of anesthesiology,
Copied contents to your clipboard!